Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 271 AL 285

Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Fujino T, Yamada T, Asada T, Tsuboi Y, Wakana C, Mawatari S, Kono S.

EBioMedicine. 2017 Mar;17:199-205. doi: 10.1016/j.ebiom.2017.02.012. Epub 2017 Feb 24.

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients

Ketter N, Brashear HR, Bogert J, Di J, Miaux Y, Gass A, Purcell DD, Barkhof F, Arrighi HM.

J Alzheimers Dis. 2017;57(2):557-573. doi: 10.3233/JAD-160216.

An update on the advancements in the treatment of agitation in Alzheimer's disease

Porsteinsson AP, Antonsdottir IM.

Expert Opin Pharmacother. 2017 Apr;18(6):611-620. doi: 10.1080/14656566.2017.1307340. Epub 2017 Mar 28.

[Alzheimer's disease]

Høgh P.

Ugeskr Laeger. 2017 Mar 20;179(12):V09160686.

Vitamin E for Alzheimer's dementia and mild cognitive impairment

Farina N, Llewellyn D, Isaac MGEKN, Tabet N.

Cochrane Database Syst Rev. 2017 Apr 18;4(4):CD002854. doi: 10.1002/14651858.CD002854.pub5.

Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study

Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, Detre JA, Wolk DA, Arnold SE.

Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):107-113. doi: 10.1097/WAD.0000000000000202.

Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia

Viscogliosi G, Chiriac IM, Ettorre E.

J Am Med Dir Assoc. 2017 Sep 1;18(9):799-802. doi: 10.1016/j.jamda.2017.06.010. Epub 2017 Jul 21.

[Role of Mediterranean diet on the prevention of Alzheimer disease]

Miranda A, Gómez-Gaete C, Mennickent S.

Rev Med Chil. 2017 Apr;145(4):501-507. doi: 10.4067/S0034-98872017000400010.

[Efficacy and tolerance of Memantine monotherapy and combination therapy with Reinhartdt And Sea Cucumber Capsule on agitation in moderate to severe Alzheimer disease]

Yu EY, Liao ZL, Tan YF, Qiu YJ, Zhu JP, Chen Y, Lin SS, Wu MH.

Zhonghua Yi Xue Za Zhi. 2017 Jul 18;97(27):2091-2094. doi: 10.3760/cma.j.issn.0376-2491.2017.27.003.

Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease

Prickaerts J, Heckman PRA, Blokland A.

Expert Opin Investig Drugs. 2017 Sep;26(9):1033-1048. doi: 10.1080/13543784.2017.1364360. Epub 2017 Aug 9.

Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases

Clapcote SJ.

Adv Neurobiol. 2017;17:103-131. doi: 10.1007/978-3-319-58811-7_5.

Using transcranial direct current stimulation to treat symptoms in mild cognitive impairment and Alzheimer's disease

Liu CS, Rau A, Gallagher D, Rajji TK, Lanctôt KL, Herrmann N.

Neurodegener Dis Manag. 2017 Oct;7(5):317-329. doi: 10.2217/nmt-2017-0021. Epub 2017 Oct 18.

Understanding and Supporting Persons With Memory Loss and Their Families Across the Spectrum of Dementia

Gaugler JE.

J Appl Gerontol. 2017 Jul;36(7):779-781. doi: 10.1177/0733464817710755.

Alzheimer disease in 2016: Putting AD treatments and biomarkers to the test

Reiman EM.

Nat Rev Neurol. 2017 Feb;13(2):74-76. doi: 10.1038/nrneurol.2017.1. Epub 2017 Jan 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias